Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ShangPharma Accepts $9/ADS Go-Private Offer

publication date: Dec 21, 2012
ShangPharma, a pre-clinical CRO headquartered in Shanghai’s Zhangjiang Hi-Tech Park, has agreed to a go-private offer of $9.00 per ADS. The offer was made by a group comprised of Michael Xin Hui, the company’s Chairman/CEO/Founder, and TPG, a US private equity group that has long been an investor in ShangPharma. Mr. Hui currently controls 54% of the company’s shares, while TPG still owns 11%. TPG will presumably fund at least some of the purchase of the remaining 35% of outstanding shares. The deal values ShangPharma at $173 million. More details....

Stock Symbol: (NYSE: SHP)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital